C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.46 AUD 8.15% Market Closed
Market Cap: 162.3m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Net Margin
Cyclopharm Ltd

-32.1%
Current
-24%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-32.1%
=
Net Income
-9.3m
/
Revenue
29m

Net Margin Across Competitors

Country AU
Market Cap 162.3m AUD
Net Margin
-32%
Country US
Market Cap 205.2B USD
Net Margin
14%
Country US
Market Cap 193.1B USD
Net Margin
29%
Country US
Market Cap 148.6B USD
Net Margin
16%
Country US
Market Cap 132.9B USD
Net Margin
11%
Country IE
Market Cap 109.9B USD
Net Margin
13%
Country US
Market Cap 64.8B USD
Net Margin
9%
Country DE
Market Cap 56.6B EUR
Net Margin
8%
Country CN
Market Cap 326.2B CNY
Net Margin
33%
Country US
Market Cap 42.2B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
162.3m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.05 AUD
Undervaluation 29%
Intrinsic Value
Price
C

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-32.1%
=
Net Income
-9.3m
/
Revenue
29m
What is the Net Margin of Cyclopharm Ltd?

Based on Cyclopharm Ltd's most recent financial statements, the company has Net Margin of -32.1%.